|By JCN Newswire||
|April 24, 2014 12:05 AM EDT||
Many developing countries throughout the world are faced with problems of Access to Medicines (ATM), which occurs when issues such as poverty and underdeveloped medical systems result in essential medicines being unable to reach the people who need them. This is especially the case with NTDs, which are a group of tropical infections that are endemic to 149 countries worldwide, primarily affecting poor people in developing and emerging countries with over 1 billion people infected. Despite most of these diseases having been treated and eliminated already in developed countries, in countries which are endemic to NTDs, patients are unable to get access to medical treatment, which is a global access to medicines issue. This is caused by a number of complex factors in endemic countries such as inadequate medical supply systems, a lack of information about diseases, and the limited adoption of disease diagnosis, prevention and treatment methods. In order to solve these issues, co-operation between governments, non-government organizations (NGOs) and pharmaceutical companies is required.
The "Eisai ATM Navigator" provides content that explains the causes, symptoms, infected regions, treatments and prevention methods for the 17 NTDs prioritized by the World Health Organization (WHO) as well as the three infectious diseases of HIV/AIDS, malaria and tuberculosis, in an easy to understand way. The website is for patients, the general public, healthcare professionals and volunteers in both developed and endemic countries. The website also introduces elimination initiatives implemented by pharmaceutical companies and other organizations.
Providing this kind of information through the website, Eisai aims to promote awareness regarding issues of Access to Medicines and NTDs among people around the world, as well as increase understanding of these diseases among people such as patients who suffer from NTDs, those at risk of infection, local healthcare professionals and volunteers, in order to help contribute toward the future elimination of NTDs.
1. About the "Eisai Access to Medicines (ATM) Navigator" Website
This is the first Japanese and English bilingual website that comprehensively provides information on topics such as NTDs, HIV/AIDS, malaria and tuberculosis, initiatives to eliminate these diseases and improve Access to Medicines for patients, the general public, healthcare professionals and volunteers in both developed and disease endemic countries. Giving consideration to the increasing usage of smartphones around the world, the website is also designed so that people in affected regions can easily view the site on smartphones as well.
The content on this website is supervised by tropical medicine researchers Dr. Tsutomu Takeuchi, Professor Emeritus and Visiting Senior Research Fellow at the Keio University Global Security Research Institute, and Dr. Hiroyoshi Endo, Professor at the Department of International Affairs and Tropical Medicine, School of Medicine, Tokyo Women's Medical University.
The main contents provided on the site are as follows:
- What is ATM: Outlines the definition of the "Access to Medicines Issue" and approaches toward improving Access to Medicines. The issue of access to medicines is that proper medicines and medical treatments are unavailable to patients in need for reasons of poverty, underdeveloped healthcare systems or other factors, particularly in the context of high-growth emerging countries and the developing world.
- About NTDs: Explains the causes, symptoms, infected regions, treatment and prevention methods of the 17 NTDs prioritized by WHO in an easy to understand way.
- Eliminating Lymphatic Filariasis: Introduces Eisai's initiatives to eliminate lymphatic filariasis. DEC (diethylcarbamazine) is one of the three drugs used to treat lymphatic filariasis and is in short supply around the world. Eisai is producing high quality DEC tablets and providing them for free to endemic countries through WHO's mass drug administration programs in order to achieve the goal of eliminating lymphatic filariasis by 2020.
- New Drug Development: Advanced countries have not been enthusiastic in developing new drugs or vaccines for the NTDs affecting developing and emerging countries because demand is low in their own countries. As a result, there are very few effective new drugs for many of these diseases even today. This section introduces examples of international collaboration in research and development which aim to create new drugs to address these needs.
- Field Reports: Presents reports by Eisai and its supporters on Access to Medicines initiatives being implemented around the world.
2. About Neglected Tropical Diseases (NTDs)
Neglected tropical diseases (NTDs) include 17 tropical diseases that the WHO (World Health Organization) identifies as diseases that the world must overcome. Prominent among them are lymphatic filariasis, Chagas' disease, and dengue fever.
NTDs are endemic in 149 countries, infecting some 1 billion people and creating serious social difficulties. Among these countries, two NTDs are endemic in 100 countries and territories, while more than six NTDs are endemic in 30 countries and territories.
Although the spread of NTDs is mainly caused by poor hygienic conditions associated with poverty, infections from these diseases may result in serious physical impairment which in turn leads to declines in the work force and productivity, thereby hampering efforts to escape from impoverished conditions. As such, the prevalence of NTDs is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.
*The 17 NTDs are: Lymphatic filariasis, Chagas' disease, the leishmaniases, dracunculiasis, human African trypanosomiasis, blinding trachoma, leprosy, schistosomiasis, onchocerciasis, soil-transmitted helminthiasis, Buruli ulcer, dengue fever, cysticercosis, rabies, echinococcosis, foodborne trematodiases and endemic treponematoses
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Back in February of 2017, Andrew Clay Schafer of Pivotal tweeted the following: “seriously tho, the whole software industry is stuck on deployment when we desperately need architecture and telemetry.” Intrigue in a 140 characters. For me, I hear Andrew saying, “we’re jumping to step 5 before we’ve successfully completed steps 1-4.”
Apr. 28, 2017 02:00 PM EDT Reads: 1,880
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
Apr. 28, 2017 01:30 PM EDT Reads: 1,671
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
Apr. 28, 2017 01:15 PM EDT Reads: 2,771
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTred processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Apr. 28, 2017 12:45 PM EDT Reads: 2,919
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Apr. 28, 2017 12:45 PM EDT Reads: 1,611
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Analytic. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
Apr. 28, 2017 12:00 PM EDT Reads: 1,352
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Apr. 28, 2017 11:45 AM EDT Reads: 1,352
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
Apr. 28, 2017 11:30 AM EDT Reads: 2,048
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Apr. 28, 2017 11:30 AM EDT Reads: 1,732
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
Apr. 28, 2017 11:30 AM EDT Reads: 2,492
SYS-CON Events announced today that Hitachi Data Systems, a wholly owned subsidiary of Hitachi LTD., will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City. Hitachi Data Systems (HDS) will be featuring the Hitachi Content Platform (HCP) portfolio. This is the industry’s only offering that allows organizations to bring together object storage, file sync and share, cloud storage gateways, and sophisticated search an...
Apr. 28, 2017 11:15 AM EDT Reads: 690
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
Apr. 28, 2017 11:00 AM EDT Reads: 680
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Apr. 28, 2017 11:00 AM EDT Reads: 2,248
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
Apr. 28, 2017 11:00 AM EDT Reads: 510
Quickly find the root cause of complex database problems slowing down your applications. Up to 88% of all application performance issues are related to the database. DPA’s unique response time analysis shows you exactly what needs fixing - in four clicks or less. Optimize performance anywhere. Database Performance Analyzer monitors on-premises, on VMware®, and in the Cloud, including Amazon® AWS and Azure™ virtual machines.
Apr. 28, 2017 11:00 AM EDT Reads: 2,041